Literature DB >> 2524231

Clinical features of common acute lymphoblastic leukemia antigen (CALLA)-positive myeloma: report of four cases.

J Tamura1, H Kurabayashi, M Sawamura, H Murakami, E Nogiwa, S Shinonome, S Miyawaki, K Kubota, S Sato, M Omine.   

Abstract

Four patients with common acute lymphoblastic leukemia antigen (CALLA)-positive myeloma are presented. The subclasses of monoclonal protein were IgD kappa (1 case), IgA lambda (1 case), and IgA kappa (2 cases). Bence Jones proteinuria was seen in all cases. The clinical stages were determined as IIA (2 cases) and IIIA (2 cases). All patients died with a median survival time after diagnosis of 62 days due to rapid development of renal failure (3 cases), and renal insufficiency and pneumonia (1 case). According to light microscopic evaluation, these myelomas corresponded to plasmablastic (1 case), immature (2 cases), and intermediate (1 case) types. Both CALLA and a cytoplasmic immunoglobulin identical with the serum monoclonal protein were simultaneously detected in single cells from all cases using immunofluorescent double labeling. These findings suggest that CALLA-positive and plasma-blastic myelomas constitute clinically a subgroup characterized by extremely poor survival but they represent cytologically different subcategories.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524231     DOI: 10.1007/bf00320910

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  11 in total

1.  The bone marrow on sternal aspiration in multiple myeloma.

Authors:  E D BAYRD
Journal:  Blood       Date:  1948-09       Impact factor: 22.113

2.  Multiple myeloma: circulating lymphocytes that express plasma cell antigens.

Authors:  G J Ruiz-Argüelles; J A Katzmann; P R Greipp; N J Gonchoroff; J P Garton; R A Kyle
Journal:  Blood       Date:  1984-08       Impact factor: 22.113

3.  Prognostic relevance of cellular morphology in multiple myeloma.

Authors:  E Fritz; H Ludwig; M Kundi
Journal:  Blood       Date:  1984-05       Impact factor: 22.113

4.  Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.

Authors:  B G Durie; S E Salmon; T E Moon
Journal:  Blood       Date:  1980-03       Impact factor: 22.113

5.  Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.

Authors:  F Caligaris-Cappio; L Bergui; L Tesio; G Pizzolo; F Malavasi; M Chilosi; D Campana; B van Camp; G Janossy
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

6.  Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging.

Authors:  R Bartl; B Frisch; R Burkhardt; A Fateh-Moghadam; G Mahl; P Gierster; M Sund; G Kettner
Journal:  Br J Haematol       Date:  1982-07       Impact factor: 6.998

7.  CALLA-positive myeloma: an aggressive subtype with poor survival.

Authors:  B G Durie; T M Grogan
Journal:  Blood       Date:  1985-07       Impact factor: 22.113

8.  Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.

Authors:  R Bataille; B G Durie; J Grenier
Journal:  Br J Haematol       Date:  1983-11       Impact factor: 6.998

9.  Multiple myeloma: significance of plasmablastic subtype in morphological classification.

Authors:  P R Greipp; N M Raymond; R A Kyle; W M O'Fallon
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

10.  Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues.

Authors:  R S Metzgar; M J Borowitz; N H Jones; B L Dowell
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

View more
  1 in total

1.  Nonsecretion of myeloma protein in spite of an increase in tumor burden by chemotherapy.

Authors:  K Kubota; H Kurabayashi; E Kawada; K Okamoto; J Tamura; T Shirakura
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.